About Imaginab
ImaginAb: Pioneering Biotech Company Innovating for Tomorrow
ImaginAb is a pioneering biotech company that is leading the way in modern radiopharmaceutical advances. The company's advanced imaging solutions, such as CD8, are revolutionizing the field of cancer immunotherapy and helping to improve patient outcomes.
Founded in 2007, ImaginAb has quickly established itself as a leader in the development of novel imaging agents for use in clinical trials and patient care. The company's proprietary technology platform allows for the rapid discovery and optimization of high-affinity antibodies that can be used to target specific disease markers.
One of ImaginAb's most exciting innovations is its CD8 ImmunoPET technology. This groundbreaking approach uses PET imaging to visualize T cells within tumors, providing clinicians with valuable information about how well a patient's immune system is responding to treatment.
In addition to its work in cancer immunotherapy, ImaginAb is also developing imaging agents for use in other areas of medicine. For example, the company has partnered with pharmaceutical companies to develop new drugs for Alzheimer's disease and other neurodegenerative disorders.
ImaginAb has received numerous awards and accolades for its innovative work. In 2019, the company was named one of FierceBiotech's "Fierce 15" companies – a list that recognizes the most promising private biotech firms around the world.
At ImaginAb, innovation isn't just a buzzword – it's at the heart of everything we do. Our team of scientists and researchers are constantly pushing boundaries and exploring new ways to improve patient outcomes through advanced imaging solutions.
If you're looking for a partner who shares your commitment to innovation and excellence, look no further than ImaginAb. Contact us today to learn more about our cutting-edge technologies and how they can help you achieve your research goals.